Browse Articles

Testing HCN1 channel dysregulation in the prefrontal cortex using a novel piezoelectric silk neuromodulator

Mathew et al. | May 05, 2021

Testing HCN1 channel dysregulation in the prefrontal cortex using a novel piezoelectric silk neuromodulator

Although no comprehensive characterization of schizophrenia exists, there is a general consensus that patients have electrical dysfunction in the prefrontal cortex. The authors designed a novel piezoelectric silk-based implant and optimized electrical output through the addition of conductive materials zinc oxide (ZnO) and aluminum nitride (AlN). With further research and compatibility studies, this implant could rectify electrical misfiring in the infralimbic prefrontal cortex.

Read More...

A Novel Approach to Prevent and Restrict Early Stages of Cancer Cell Growth Using a Combination of Moringa and Sesame in a Drosophila Model

Ganesh et al. | Sep 28, 2020

A Novel Approach to Prevent and Restrict Early Stages of Cancer Cell Growth Using a Combination of Moringa and Sesame in a <em>Drosophila</em> Model

Sesame (Sesamum indicum) and moringa (Moringa oleifera) have natural antioxidants that could prevent cancer growth. Previously, this group found that sesame and moringa individually suppress eye tumor grown in the Drosophila melanogaster model. In the present study, combinations of sesame and moringa at different concentrations were included in the D. melanogaster diet. The impact on eye tumor development was assessed at different stages of growth.

Read More...

Effect of the Herbal Formulation HF1 on the Expression of PD-L1 in PC3 cells

Imani et al. | Nov 15, 2019

Effect of the Herbal Formulation HF1 on the Expression of PD-L1 in PC3 cells

In this study, Imani et al. investigate whether a new proprietary herbal formulation, HF1, can inhibit expression of immune suppressor protein PD-L1. PD-L1 is a transmembrane protein that can be expressed by cancer cells to assist in their ability to avoid attacks from the immune system. Work from this study demonstrates that HF1 treatment can reduce expression of PD-L1 in cultured cancer cells, implicating HF1 as a potential new cancer therapy.

Read More...

Synergistic Effects of Metformin and Captopril on C. elegans

Kadıoğlu et al. | Jul 10, 2018

Synergistic Effects of Metformin and Captopril on <em>C. elegans</em>

Kadıoğlu and Oğuzalp study the synergistic effects of Metformin and Captopril, two commonly prescribed drugs for type 2 diabetes and hypertension, respectively. Using C. elegans nematodes as a model system, the authors find that the nematodes decreased in average body length when exposed to Metformin or Captopril individually, but grew 11% in body length when both drugs were used together. Because C. elegans body size is regulated in part by the TGF-β signaling pathway, the authors suggest that synergistic effects of these two drugs may be modulating TGF-β activity, a previously uncharacterized phenomenon.

Read More...

Zinc-related Treatments Combined with Chloroquine and Gemcitabine for Treating Pancreatic Cancer

Ma et al. | Sep 11, 2021

Zinc-related Treatments Combined with Chloroquine and Gemcitabine for Treating Pancreatic Cancer

Pancreatic cancer is one of the deadliest cancers, with a 10% 5-year survival rate. The authors studied various dosages of TPEN and zinc in combination with Chloroquine and Gemcitabine as treatments to reduce cell proliferation. Results showed that when combined with Chloroquine and Gemcitabine, zinc and TPEN both significantly lowered cell proliferation compared to Gemcitabine, suggesting a synergistic effect that resulted in a more cytotoxic treatment. Further research and clinical trials on this topic are needed to determine whether this could be a viable treatment for pancreatic cancer.

Read More...

Search Articles

Search articles by title, author name, or tags

Clear all filters

Popular Tags

Browse by school level